How much does the original drug Adagrasib cost?

Adagrasib is a new KRAS G12C inhibitor, mainly used to treat patients with non-small cell lung cancer and other tumors that carry this mutation. Due to its difficulty in research and development and its relatively precise indications, it is still a high-end innovative targeted drug globally. The original drug was developed by Mirati Therapeutics of the United States and was approved by the FDA in 2022. Since it has not yet been officially approved in China, patients who need to use the drug can only obtain it through overseas purchase channels.

Currently, the original drug of adagrasibu on the U.S. market is extremely expensive. According to information from public channels, the cost of a box of medicines can be as high as RMB 100,000 or so. The specific price will fluctuate depending on the dosage, specifications and purchase method of the medicines. This price is burdensome for most ordinary patients, so price-sensitive patients will tend to look for alternative channels or generic versions.

Compared with the high price of original drugs, the generic drugs of adagrasibu provided by some foreign countries have become a more feasible alternative. Among them, the Laos imitation version is the most common and stable, with each box selling for about more than 3,000 yuan. Although it is a generic drug, its ingredients are basically the same as the original drug, and some channels can provide ingredient consistency test reports from third-party laboratories, so it has obvious advantages in terms of cost performance.

It needs to be reminded that whether you choose original drugs or generic drugs, you should use them under the guidance of a professional doctor and ensure that the source of the drugs is formal and reliable. At present, many patients have obtained the drug through cross-border medical services, international pharmacy purchasing agents, etc. Patients are advised to remain vigilant when seeking to purchase and avoid mistakenly purchasing counterfeit or inferior drugs due to the pursuit of low prices. With the further promotion of adagrasib around the world, the price may gradually drop in the future, and it is even expected to be included in the medical insurance system, thus reducing the financial burden on patients.

Reference materials:https://www.drugs.com/